Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2019

View Archived Issues

"Neoleukins" better than the real thing

"Exercise hormone" has role in synaptic plasticity, memory

KPNA1 influences sphingosine-sensitive anxiety pathways by regulating MeCP2 nuclear import

Orion Biotechnology's OB-002O reduces colorectal tumor growth in vivo

Novel insights into targets and mechanisms behind the neuroprotective effect of N-Acetylcysteine

VISTA found a potential therapeutic target in pancreatic cancer

Biomunex and Sanofi enter licensing agreement for bi- and multi-specific antibody therapeutics

Anti-CTLA-4 dual variable domain preserves antitumor effects while eliminating toxicity

EMA grants marketing authorization for macimorelin

Erleada approved in Europe for patients with nmCRPC at high risk of developing metastatic disease

Phase IIa study of UB-311 meets primary endpoint in patients with Alzheimer's disease

Pulmotect initiates phase II study of PUL-042

Top-line data presented from phase II study of NYX-2925 in painful diabetic peripheral neuropathy

How chondrocytes make the best of low-oxygen state

Chinfloxacin shows promising PK and safety profile in first-in-human study

Dual PI3K/HDAC inhibitors discovered at the U.S. Department of Health & Human Services

Macrophage integrin CD11b as novel therapeutic target for cancer immunotherapy

Ralexar Therapeutics patents oxysterols receptor LXR-beta agonists

FDA issues complete response letter for Opsumit sNDA for CTEPH

FDA clears IND for phase Ib study of Aivita's AV-MEL-1 in metastatic melanoma

Pharmaxis eyes phase II studies with LOXL2 inhibitors following completion of toxicity studies

ADC Therapeutics begins phase I trial of ADCT-601 in advanced or metastatic solid tumors

FDA accepts IND for phase Ib/IIa study of Hyleukin-7 with atezolizumab in high-risk skin cancers

Celleron completes phase Ib evaluation of CXD-101 with nivolumab

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...